Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3773383 | 0.83 | NR4A2 (0.58) | NR4A2CYP2C9KDM4ERAB9ANPC1 | |
| SCHEMBL4211423 | 0.81 | RAB9A (0.53) | HRH4HRH3NR4A2CYP2C9KDM4E | |
| SCHEMBL4213158 | 0.78 | HRH4 (0.55) | HRH4HRH3KDM4ERAB9ANPC1 | |
| SCHEMBL2086757 | 0.77 | RAB9A (0.52) | HRH4HRH3KDM4ERAB9ANPC1 | |
| SCHEMBL299158 | 0.76 | HRH4 (0.58) | HRH4HRH3KDM4ERAB9ANPC1 | |
| SCHEMBL4242240 | 0.75 | EGLN1 (0.53) | HRH4HRH3NR4A2KDM4ERAB9A | |
| SCHEMBL1578499 | 0.75 | GRM5 (0.45) | NR4A2CYP2C9KDM4ERAB9A | |
| SCHEMBL2086752 | 0.74 | HRH4 (0.54) | HRH4HRH3KDM4ERAB9ANPC1 | |
| SCHEMBL20646875 | 0.74 | HRH4 (0.61) | HRH4HRH3KDM4ERAB9ANPC1 | |
| SCHEMBL741720 | 0.74 | HRH4 (0.57) | HRH4HRH3KDM4ERAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160263189-A1 | TREATMENT OF A NEURODEGENERATIVE DISEASE OR DISORDER | ACADIA PHARMACEUTICALS INC. | 2016-09-15 | — | — | US | claimed |
| WO-2015059632-A1 | TREATMENT OF A NEURODEGENERATIVE DISEASE OR DISORDER | ACADIA PHARMACEUTICALS INC. (US) | 2015-04-30 | — | — | WO | claimed |
| US-20100317688-A1 | 2-HETEROAROYLIMIDAZOL[1,2-a]PYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-12-16 | — | — | US | claimed |
| US-20160263189-A1 | TREATMENT OF A NEURODEGENERATIVE DISEASE OR DISORDER | ACADIA PHARMACEUTICALS INC. | 2016-09-15 | — | — | US | disclosed |
| WO-2015059632-A1 | TREATMENT OF A NEURODEGENERATIVE DISEASE OR DISORDER | ACADIA PHARMACEUTICALS INC. (US) | 2015-04-30 | — | — | WO | disclosed |
| US-20100317688-A1 | 2-HETEROAROYLIMIDAZOL[1,2-a]PYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-12-16 | — | — | US | disclosed |
| EP-2240480-A2 | DERIVATIVES OF 2-HETEROAROYL-IMIDAZOL(1,2-A)PYRIDINE,PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | Sanofi-Aventis (FR) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009106752-A2 | DERIVATIVES OF 2-HETEROAROYL-IMIDAZOL[1,2-A]PYRIDINE, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317688-A1 | 2-HETEROAROYLIMIDAZOL[1,2-a]PYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | XDH, CYP11B2, IL4I1 | HRH4 140/4885HRH3 96/4885NR4A2 3136/4885 |
| US-20160263189-A1 | TREATMENT OF A NEURODEGENERATIVE DISEASE OR DISORDER | NCOR1, NR4A2, NR4A3 | HRH4 1951/4885HRH3 1864/4885NR4A2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.